A comparison of cell cycle markers in well-differentiated lobular and ductal carcinomas

Breast Cancer Research and Treatment

Volumn 61, Issue 2, 2000, Pages 161-170

  Soslow, Robert A ^a,d   Carlson, Diane L ^a   Horenstein, Marcelo G ^b   Osborne, Michael P ^c  

^a Department of Obstetrics Gynecology   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^c NYPH WMC and Strang Cancer Prev C ^*  (United States)

^d WMC   (United States)

Author keywords

Breast cancer; Cell cycle; Ductal; Histologic subtypes; Lobular

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P27; PROTEIN P53; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER RESEARCH; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; METASTASIS; MOLECULAR GENETICS; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

ANTIGENS, NEOPLASM; ANTIGENS, NUCLEAR; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL CYCLE; CELL CYCLE PROTEINS; COHORT STUDIES; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOPHENOTYPING; KI-67 ANTIGEN; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0033934359     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006479113769     Document Type: Article

References (48)

1. 1. Winchester DJ, Chang HR, Graves TA, Menck HR, Bland KI, Winchester, DP: A Comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment and outcomes. J Am Coll Surg 186: 416-422, 1988
2. 2. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon, A, Beuzeboc P, Dorval T, Durand JC, Fourquet A, Pouillart, P: Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77: 113-120, 1996
3. 3. Du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Robertson JF, Blarney RW: An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 17: 251-257, 1991
4. 4. Weiss MC, Fowble BL, Solin LJ, Yeh IT, Schultz DJ: Outcome of conservation therapy for invasive breast cancer by histologic subtype. Int J Radial Oncol Biol Phys 23: 941-947, 1992
5. 5. Tiokkanen S, Pylkkanen L, Joensuu H: Invasive lobular carcinoma of the breast has better short-and long-term survival than invasive ductal carcinoma. Br J Cancer 76: 1234-1240, 1997
6. 6. DiCostanzo D, Rosen PP, Careen I, Franklin S, Lesser M: Prognosis in infiltrating lobular carcinoma. An analysis of classical and variant tumors. Am J Surg Pathol 14: 12-23, 1990
7. 7. Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colbum WJ, Senofsky, GM Gamagami P: Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 73: 1673-1677, 1999
8. 8. Du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Blarney RW: Invasive lobular carcinomas of the breast - the prognosis of histopathological subtypes. Br J Cancer 60: 605-609, 1989
9. 9. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy, SW: Infiltrating lobular carcinoma of the breast. Histopathol 6: 149-161, 1982
10. 10. Fechner RE: Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol 6: 373-378, 1975
11. 11. Weidner N, Semple JP: Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 23: 1167-1171, 1992
12. 12. Bentz JS, Yassa N, Clayton F: Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol 11: 814-822, 1988
13. 13. Raju U, Ma CK, Shaw A: Signet ring variant of lobular carcinoma of the breast; a clinicopathologic and immunohistochemical study. Mod Pathol 6: 515-520, 1993
14. 14. Merino MJ, LiVolsi VA: Signet ring carcinoma of the female breast. A clinicopathologic analysis of 24 cases. Cancer 48: 1830-1837, 1981
15. 15. Cserni G: Reproducibility of a diagnosis of invasive lobular carcinoma. J Surg Oncol 70: 217-221, 1999
16. 16. Dixon AR, Ellis IO, Elson CW, Blamey RW: A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. Br J Cancer 63: 634-635, 1991
17. 17. Borst MJ, Ingold JA: Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114: 637-641, 1993
18. 18. Lamovec I, Zidar A: Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med 115: 507-510, 1991
19. 19. Harris M, Howell A. Chrissohou M, Swindell RI, Hudson M, Sellwood RA: A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer 50: 23-30, 1984
20. 20. Lamovec J, Bracko M: Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 48: 28-33, 1991
21. 21. Jain S, Fisher C, Smith P, Millis RR, Rubens RD: Patterns of metastatic breast cancer in relation to histological type. Eur J Cancer 29A: 2155-2157, 1993
22. 22. Courjal F, Louason G, Speiser P, Katsaros R, Zeillinger R, Theillet C: Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69: 247-253, 1996
23. 23. van Diest PJ, Michalides RJAM, Jannink I, van der Valk P, Pelersen HL, de Jong JS, Meijer CJL, Baak JPA: Cyclin D1 expression in invasive breast cancer. Am J Pathol 150: 705-711, 1997
24. 24. World Health Organization: Histological typing of breast tumors. Tumori 68: 181-198, 1982
25. 25. Sobin LH, Wittekin C (eds): TNM Classification of Malignant Tumors, 5th edition. Wiley-Liss, 1997
26. 26. Remmele W, Schicketanz K-H: Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Path Res Pract 8: 227-245, 1993
27. 27. Soslow RA, Shen P, Chung MH, Isacson C: Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated uterine carcinoma. Int J Gynecol Pathol 17: 129-134, 1998
28. 28. Makkink-Nombrado SV, Baak JP, Schuurmans L, Theeuwes JW, van der Aa T: Quantitative immunohistochemistry using the CAS 200/486 image analysis system in invasive breast carcinoma: a reproducibility study. Anal Cell Pathol 8: 227-245, 1995
29. 29. Blanco G, Alavaikko M, Ojala A, Collan Y, Heikkinen M, Heitanen T, Aine R, Taskinen PJ: Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients. Anticancer Res 4: 383-389, 1984
30. 30. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43: 2985-2990, 1983
31. 31. Aranda FI, Laforga JB: Cellular proliferation in breast ductal infiltrating carcinoma. Correlation with clinical and histopathological variables. Pathol Res Pract 193: 683-688, 1997
32. 32. Moriki T, Takahashi T, Hiroi M, Yamane T, Hara H: Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: an immunohistochemical study including correlations with p53, c-erbB-2 and estrogen receptor status. Pathol Int 46: 417-425, 1996
33. 33. Wright C, Angus B, Nicholson S, Sainbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087-2090, 1989
34. 34. McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BM, Carney DN: Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 51: 3296-3303, 1991
35. 35. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405-415, 1997
36. 36. Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW, Sutherland RL: Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 272: 10882-10894, 1997
37. 37. Shi-Yu Zhang, Caamano J, Cooper F, Guo Xu, Klein-Szanto, AJP: Immunohistochemistry of cyclin D1 in human breast cancer. Am J Clin Pathol 102: 695-698, 1994
38. 38. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Henry JA, Angus B, Lennard TWJ, Horne CHW: Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene 11: 885-891, 1995
39. kip1 expression in endocrine and other tumors. A J Pathol 150: 401-407, 1997
40. 40. Wu J, Shen ZZ, Lu JS, Jiang M, Han QX, Fontana JA, Barsky SH, Shao ZM: Prognostic role of p27kip1 and apoptosis in human breast cancer. Br J Cancer 79: 1572-1578, 1999
41. 41. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S: Relationship between p53 expression and other prognostic factors in human breast carcinoma. An immunohistochemical study. Am J CIin Pathol 100: 213-217, 1993
42. 42. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Dalla P: p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98: 408-418, 1992
43. 43. Bhargava V, Kell DL, van de Rijn M, Warnke, RA: Bcl-2 immunoreactivity in breast carcinomas correlates with hormone receptor positivity. Am J Pathol 1145, 535-540, 1994
44. 44. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W: Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Ann Oncol 6: 1005-1010, 1995
45. 45. McCann AH, Kirley A, Carney DN, Corhally N, Magee HM, Keating G, Dervan PA: Amplification of the MDM2 gene in human breast cancer and its associated with MDM2 and p53 protein status. Br J Cancer 71: 981-985, 1995
46. 46. Marchetti A, Buttitta F, Girlando S, Palma Paolo Dalla, Pellegrini S, Fina Paolo, Doglionis C, Bevilacqua G, Barhureschi M: mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 175: 31-38, 1995
47. 47. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM: Simultaneous loss of e-eadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183: 404-411, 1997
48. 48. Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, Cornelisse C: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13: 1919-1925, 1996